Feds extend telemedicine prescribing for up to 18 more months
When the federal COVID-19 Public Health Emergency comes to an end May 11, people will be able to continue getting prescriptions for drugs that treat ADHD, opioid use disorder and other conditions from medical providers via telehealth for as many as 18 more months.
When the federal COVID-19 Public Health Emergency comes to an end on May 11, people will be able to continue getting prescriptions for drugs that treat ADHD, opioid use disorder and other conditions from medical providers via telehealth – for as many as 18 more months.
Before the pandemic, medications classified as controlled substances could only be initially prescribed after an in-person examination. In the early months of the pandemic, with medical offices closed to in-person visits, the Drug Enforcement Administration issued a waiver allowing prescriptions for these medications to be started via telehealth.
The new extension allows providers to initiate new prescriptions through telehealth until November 11, 2023 and to continue prescribing that started before that date for another year – through November 11, 2024.
Previous extensions were set to expire tomorrow, a prospect that alarmed many patients and providers, leading to the submission of more than 38,000 comments to the DEA as federal officals weighed new regulations. The extension allows doctors and patients to continue telehealth prescribing while the DEA reviews the comments and formulates final rules.
“We recognize the importance of telemedicine in providing Americans with access to needed medications, and we have decided to extend the current flexibilities for six months while we work to find a way forward to give Americans that access with appropriate safeguards,” DEA Administrator Anne Milgram said in a statement.
Organizations like the American Telehealth Association (ATA) – originally critical of the DEA’s plan to shift from the current waivers – were pleased.
“These actions cover access to clinically appropriate prescriptions of controlled substances that patients need for a wide variety of medical circumstances, including for mental health and substance use disorders,” Kyle Zebley, senior vice president of public policy for the ATA, said in a statement. “We are hopeful that during this extension period, the DEA will revise the draft rules to address unnecessarily restrictive barriers to equitable and appropriate clinical care, such as mandating in-person visits.”
Mental health can't wait.
America is in a mental health crisis — but too often, the media overlooks this urgent issue. MindSite News is different. We’re the only national newsroom dedicated exclusively to mental health journalism, exposing systemic failures and spotlighting lifesaving solutions. And as a nonprofit, we depend on reader support to stay independent and focused on the truth.
It takes less than one minute to make a difference. No amount is too small.
The name “MindSite News” is used with the express permission of Mindsight Institute, an educational organization offering online learning and in-person workshops in the field of mental health and wellbeing. MindSite News and Mindsight Institute are separate, unaffiliated entities that are aligned in making science accessible and promoting mental health globally.
Author
Related Articles
Homeless Camp Sweeps Can Harm Health. Some Cities Are Trying a New Way
Several cities and counties are addressing street homelessness with a new approach, which experts say can clear encampments while protecting the health of people who are forced to move.
Along the Mexico-U.S. Border, New Barriers to Harm Reduction
Border militarization is making it harder for healthcare workers to reach people who use drugs.
‘I’ve Never Seen Anything Like it.’ ICE Raids Sow Anxiety, Lead One Man to Ask: Should I Self-Deport?
Trump’s immigration crackdown is creating deep stress and fear among some longtime residents and prompting them to flee the country. They leave behind fractured communities and grieving loved ones.
